Applies to ranitidine: oral solution, oral tablets and tablets for, oral tablets effervescent for solution, parenteral injection, parenteral injection for iv infusion only
Side effects include:
Oral or parenteral therapy: Headache, sometimes severe.           
IM therapy: Transient pain at injection site.  
IV therapy: Transient local burning or itching.  
Applies to ranitidine: compounding powder, injectable solution, intravenous solution, oral capsule, oral granule effervescent, oral syrup, oral tablet, oral tablet effervescent
The most commonly reported side effect for IM administration was injection site pain, and the most commonly reported side effects with IV administration were localized pain and burning.[Ref]
Uncommon (0.1% to 1%): Abdominal discomfort/pain, constipation, nausea, vomitingVery rare (less than 0.01%): Acute pancreatitis, diarrhea[Ref]
Abdominal pain, constipation, and nausea tended to improve with continued treatment.[Ref]
Rare (0.01% to 0.1%): Hypotension, chest pain, arrhythmia, bradycardia, atrioventricular block, tachycardia, premature ventricular beatsVery rare (less than 0.01%): Asystole, vasculitis[Ref]
Bradycardia, atrioventricular block, tachycardia, and asystole have occurred in H2 receptor antagonists.[Ref]
Rare (0.01% to 0.1%): Insomnia, reversible mental confusion, agitation, depression, hallucinationsFrequency not reported: Loss of libido[Ref]
Headache may be related to administration of treatment.[Ref]
Rare (0.01% to 0.1%): Dizziness, somnolence, vertigo, reversible involuntary movement disordersVery rare (less than 0.01%): Headache/severe headache[Ref]
Rare (0.01% to 0.1%): Urticaria, angioneurotic edema, skin rashVery rare (less than 0.01%): Erythema multiforme, alopecia[Ref]
Very rare (less than 0.01%): Musculoskeletal symptoms, arthralgia, myalgia[Ref]
Rare (0.01% to 0.1%): Transient and reversible changes in liver function tests, increased ALT levelsVery rare (less than 0.01%): Hepatocellular/hepatocanalicular/mixed hepatitis with/without jaundice[Ref]
Hepatitis with/without jaundice were usually reversible.ALT levels increased to at least 2 times the pretreatment levels in patients receiving high IV doses for at least 5 days.[Ref]
Rare (0.01% to 0.1%): Fever, malaiseFrequency not reported: Death[Ref]
Rare (0.01% to 0.1%): Hypersensitivity reactionsVery rare (less than 0.01%): Anaphylactic shock/anaphylaxis[Ref]
Anaphylactic shock occurred after administration of a single dose.[Ref]
Rare (0.01% to 0.1%): Elevation in serum creatinineVery rare (less than 0.01%): Acute interstitial nephritis[Ref]
Elevation in serum creatinine was usually slight, and typically normalized with continued treatment.[Ref]
Rare (0.01% to 0.1%): BronchospasmFrequency not reported: Dyspnea, pneumonia[Ref]
Rare (0.01% to 0.1%): Reversible blurred vision[Ref]
Very rare (less than 0.01%): Blood count changes, leukopenia, thrombocytopenia, granulocytopenia, agranulocytosis, pancytopenia, marrow hypoplasia/aplasiaFrequency not reported: Aplastic anemia, immune hemolytic anemia/acquired immune hemolytic anemia, eosinophilia[Ref]
Leukopenia, granulocytopenia, and thrombocytopenia were usually reversible.[Ref]
Very rare (less than 0.01%): Reversible impotence, breast symptoms/conditions, galactorrhea[Ref]
Very rare (less than 0.01%): Gynecomastia[Ref]
Postmarketing reports: Acute porphyria[Ref]
Frequency not reported: Injection site pain, transient localized burning or itching[Ref]
1. "Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals, New York, NY. 
2. Cerner Multum,  Inc. "Australian Product Information." O 0
3. "Product Information. Zantac (ranitidine)." Glaxo Wellcome, Research Triangle Park, NC. 
4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
It is possible that some side effects of ranitidine may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
